|Bid||7.13 x 0|
|Ask||7.25 x 0|
|Day's Range||6.80 - 7.26|
|52 Week Range||6.47 - 18.09|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 27, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abacus Health Products, Inc. (CSE: ABCS, OTCQX:ABAHF) (“Abacus” or the “Company”) today announced that it will participate in two industry conferences: The Eight Capital & Cassels Brock Global Cannabis Conference being held on September 19, 2019 at The Shangri-La Hotel in Toronto and the Alliance Global Partners’ Consumer Cannabis Conference to be held on October 3, 2019 at The Pierre Hotel in New York City. Abacus will participate in panel discussions at both conferences to discuss the rapidly growing CBD industry and will also be available for 1x1 meetings. This news release contains forward-looking statements or information (collectively, “forward-looking statements”) within the meaning of applicable securities legislation.
Football star Rob Gronkowski is partnering with Abacus Health (ABAHF), a publicly traded CBD company listed in Canada, the maker of CBDMEDIC.
Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) reported its financial results today for the second quarter ended June 30, 2019. Purchase orders received to date represent over 3,000 retail locations across 24 states.
NEW YORK, Aug. 27, 2019 /PRNewswire/ -- Rob Gronkowski, three-time professional football champion with several records to his name, today announced that he has become an advocate for CBD and an investor in Abacus Health Products (ABCS.CN)(ABAHF) ("Abacus" or the "Company"). Abacus is the maker of CBDMEDIC, the first family of all-natural topical medications that combine over the counter (OTC) drug active ingredients with CBD-rich hemp oil and other natural moisturizers.
Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced an agreement with Rob Gronkowski (Gronk), three-time professional football champion. The agreement includes a commitment by Gronkowski to support the Company’s existing products in a manner that Abacus believes will meaningfully increase awareness with consumers and retail buyers as well as collaborate with the Company in the development and marketing of new and innovative products.
Abacus Health Products, Inc. will release its 2019 second quarter financial results sooner than previously announced. The Company will release the results on Tuesday, August 27, 2019, prior to market open.
Abacus Health Products, Inc. (ABCS.CN) (ABAHF) (“Abacus” or the “Company”) today announced the addition of Matrix Distributors, Inc. (“Matrix Distributors”) as a distributor of its CBDMEDIC™ products. The Company has also announced the expansion of retail stores carrying its products with both new and existing retail partners. Matrix Distributors, Inc., which serves over 1,000 independent pharmacies will initially roll out 9 CBDMEDIC™ products, including 6 unique pain relief SKUs, Acne Treatment Cream and Cleanser, and Eczema Treatment, to up to 250 locations across New York, New Jersey and Pennsylvania during 2019, with further roll-outs planned for 2020.
Abacus Health Products, Inc. will release its 2019 second quarter financial results on Thursday, August 29, 2019, after market close.
WOONSOCKET, RI and TORONTO , July 31, 2019 /CNW/ - Abacus Health Products, Inc. ("Abacus" or the "Company") (CSE: ABCS) (ABAHF) is pleased to announce that Mr. Hannan Fleiman has joined its board of directors. Mr. Fleiman will also serve as Chair of the Company's Audit Committee and Corporate Governance, Nominating and Compensation Committee. With the addition of Mr. Fleiman, Abacus now has a total of five directors on its board. "I am pleased to welcome Hannan Fleiman to Abacus' board of directors," said Perry Antelman , CEO of Abacus.
WOONSOCKET, RI , July 2, 2019 /CNW/ - Abacus Health Products, Inc. ("Abacus" or the "Company") (CSE: ABCS) (ABAHF) today announced its subordinate voting shares have begun trading on the OTCQX Market under the symbol "ABAHF" effective July 1, 2019 . "Having a dual listing on both the OTCQX and the CSE has been an important objective for our company," said Perry Antelman , CEO. This news release contains forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities legislation.
NEW YORK , July 1, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Abacus Health Products Inc (CSE: ABCS; ...
Abacus CEO Perry Antelman to Speak at the Inaugural Institutional Capital & Cannabis Conference Europe
TORONTO , May 30, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") reported its financial results today for the first quarter ended March 31, 2019 . CBD CLINIC continued to perform well with revenue increasing 148% YoY, from $1,433,243 to $3,553,751 , and an increase of 23% over the fourth quarter of 2018, from $2,886,412 . Purchase orders received to date represent over 2,000 retail pharmacy and supermarket locations across 11 states.
WOONSOCKET, RI and TORONTO, May 23, 2019 /PRNewswire/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced that renowned Hollywood fitness trainer and nutritional expert, Harley Pasternak, will be working with the Company to increase public awareness of its CBDMEDIC™ line of pain relief and skincare products. Pasternak holds a Master of Science in Exercise Physiology and Nutritional Sciences from the University of Toronto and an Honors Degree in Kinesiology from the University of Western Ontario.
Abacus Health Products Announces Release Date, Conference Call and Webcast Details for 2019 First Quarter Financial Results
WOONSOCKET, RI and TORONTO, May 10, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced further growth in the distribution and availability of their line of CBDMEDIC™ products. "These purchase orders, which range from six to twelve unique SKUs across our pain relief and therapeutic skincare lines, demonstrate the continued strong interest by retail chains to bring CBDMEDIC™ products onto their shelves," said Perry Antelman , CEO of Abacus. Further, a 2018 research report by Allied Market Research estimated the global topical pain relief market to be approximately US$7.4 billion in 2017.